Clinical studies recruiting near Wahroonga

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide W
Phase 3 · Sydney Adventist Hospital · Pfizer · NCT07028853 Novel Treatment Delivery of ECAP-controlled Closed-loop SCS for Chronic Pain
NA · Sydney Pain Research Centre Pty Ltd · Saluda Medical Pty Ltd · NCT04662905 Study to Evaluate Safety of C-1101 Versus Sterile Saline in Adults With Chronic Painful Lumbosacral Radiculopathy
Phase 1 · Consano Bio Research Site · Consano Bio · NCT07264270 Phase 1 Study to Evaluate the Safety and Tolerability of Intravenously Administered PYC-003
Phase 1 · Sydney Adventist Hospital · PYC Therapeutics · NCT06714006 Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC
Phase 2 · Sydney Adventist Hospital · Leiden University Medical Center · NCT05393791 A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Phase 2 · Site AU61012 · Astellas Pharma Global Development, Inc. · NCT02960022 DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors
Phase 1 · Sydney Adventist Hospital · DynamiCure Biotechnology · NCT05785754 Efficacy, Safety, and PopPK Profile of ABP-745 in Patients With Atherosclerosis
Phase 2 · Cognivus · Atom Therapeutics Co., Ltd · NCT07303777 Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PI
Phase 3 · Sydney Adventist Hospital · Relay Therapeutics, Inc. · NCT06982521 A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Canc
Phase 3 · Sydney Adventist Hospital · Janssen Research & Development, LLC · NCT07225946 Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
Phase 3 · Research Site · AstraZeneca · NCT04862663 A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants Wit
Phase 3 · Sydney Adventist Hospital · Celgene · NCT06764485 Study to Assess the Safety and Pharmacokinetics of AVD275 Injection in Patients With Osteoarthritis of the Knee
Phase 1 · Cognivus Research Group · Avidence Therapeutics · NCT07338266 N-3C01 Monotherapy and Combination With PD-(L)1 Inhibitors in Advanced Solid Tumors
Phase 1/Phase 2 · San Clinical Trials Unit · Hefei Xinzhu Biological Technology Co., Ltd. · NCT07639450 Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
Phase 3 · SAN Clinical Trials Unit · University of Sydney · NCT02582697 LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Phase 1/Phase 2 · Sydney Adventist Hospital · enGene, Inc. · NCT04752722 A Long-term Extension Study of PCI-32765 (Ibrutinib)
Phase 3 · Adventist Health Care Limited trading as San Clinical Trials · Janssen Research & Development, LLC · NCT01804686 Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (
Phase 2/Phase 3 · Sydney Adventist Hospital · CSL Behring · NCT05485961 Study of ORIC-944 in Patients With Metastatic Prostate Cancer
Phase 1 · Sydney Adventist Health · ORIC Pharmaceuticals · NCT05413421 Working Out M0 Bipolar Androgen Therapy
Phase 2 · Sydney Adventist Hospital · Australian and New Zealand Urogenital and Prostate Cancer Tr · NCT06594926 Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer
Phase 3 · Sydney Adventist Hospital · Celcuity Inc · NCT06757634

Look up another city

Look up another condition